None listed
Conditions
Interventions
Stress imaging with cardiac magnetic resonance (CMR)with half of the subjects receiving adenosine intravenously(140mcg/kg/min) for 3-6 mins once only during the CMR and the other half receiving dobutamine intravenously (maximal dose-40mcg/kg/min) once only during CMR, all subjects have an echocardiograph once only either before or after the CMR, for those subjects in the hibernating part of the study , (those patients who will have a revascularisation either coronary artery bypass graftingor per
Stress imaging with cardiac magnetic resonance (CMR)with half of the subjects receiving adenosine intravenously(140mcg/kg/min) for 3-6 mins once only during the CMR and the other half receiving dobutamine intravenously (maximal dose-40mcg/kg/min) once only during CMR, all subjects have an echocardiograph once only either before or after the CMR, for those subjects in the hibernating part of the study , (those patients who will have a revascularisation either coronary artery bypass graftingor percutaneous coronary intervention) only adenosine (140mcg/kg/min) for 3-6 mins will be used during the CMR. These subjects will have two CMR's one at baseline and then one six months post revascularisation.
Sponsors
Southern Adelaide Health Service
Study design
Allocation
Non-randomised trial
Primary purpose
Diagnosis
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. History of hypertension, left ventricular hypertrophy, exertional chest pain and/or breathlessness, normal epicardial arteries 2. Known coronary artery disease, impaired regional left ventricular function awaiting percutaneous coronary intervention or coronary artery bypass grafting
Exclusion criteria
Inability to give written informed consent, estimated Glomerular Filtration Rate(GFR)<60mls/min, extreme claustrophobia, implantable cardiac devices and other contra-indications to Magnetic Resonance Imaging(MRI) (i.e. metal in eyes), asthma or other reversible bronchospasm
Outcome results
None listed